Cargando…
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer
BACKGROUND: Pancreatic cancer (PC) represents an aggressive disease with median overall survival (OS) of less than 1 year in the front-line setting. FOLFIRINOX and gemcitabine and paclitaxel (GP) are standard of care options for these patients; however, optimal selection of therapy is challenging. M...
Autores principales: | Chen, Kuei-Ting, Madison, Russell, Moore, Jay, Jin, Dexter, Fleischmann, Zoe, Newberg, Justin, Schrock, Alexa, Bhardwaj, Neeru, Lofgren, Katherine T, He, Jie, Frampton, Garrett, Hegde, Priti, Fabrizio, David, Pishvaian, Michael J, Ebot, Ericka, Singhi, Aatur, Sokol, Ethan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400136/ https://www.ncbi.nlm.nih.gov/pubmed/37354528 http://dx.doi.org/10.1093/oncolo/oyad178 |
Ejemplares similares
-
Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer
por: Rombouts, Steffi J., et al.
Publicado: (2016) -
FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
por: Klempner, Samuel J., et al.
Publicado: (2019) -
Routinely staging gastric cancer with (18)F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery
por: Findlay, John M., et al.
Publicado: (2019) -
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature
por: Batalini, Felipe, et al.
Publicado: (2023) -
Implementing HRD technology /
Publicado: (1999)